News
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...
Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...
Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.
This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...
20h
Woman's World on MSNNew GLP-1 Called MariTide Shows 20% Weight Loss-Without a PlateauIn the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with ...
CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...
The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...
Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...
Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...
As Ohio cuts off state employees' coverage of medications for weight loss, a lawmaker who has benefited from the drugs wants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results